Market Trends of Breast Cancer Liquid Biopsy Industry
This section covers the major market trends shaping the Breast Cancer Liquid Biopsy Market according to our research experts:
The Circulating Cell-free DNA (cfDNA) Segment is Expected to Hold a Major Market Share
Circulating cell-free DNA (cfDNA) in plasma offers a non-invasive approach to monitor tumor molecular profiling in real-time at multiple time-points, detect emerging genomic alterations associated with drug resistance, and clarify cancer prognosis and diagnosis of cancer recurrence or progression. There are many companies that offer cfDNA-based products for use in research purposes. For example, Germany-based Qiagen offers the QIAamp circulating nucleic acid kit used in a column-based method to isolate cfDNA from plasma and serum. Genomics For Life Pty Ltd is a Queensland, Australia-based company that offers genetic testing for cfDNA from blood samples. It is a major private-sector company that provides cfDNA-based testing services in Australia.
According to the World Health Organization (WHO), in 2018, it was estimated that approximately 627,000 women died from breast cancer, which is nearly 15% of all cancer deaths among women globally. Due to technological advancements in breast cancer liquid biopsy, the circulating cell-free DNA segment is anticipated to show significant development. Bio-Rad Laboratories Inc. offers the 'QX200 Droplet Digital PCR (ddPCR)' system, which provides absolute quantification of target DNA or RNA molecules for EvaGreen or probe-based digital PCR applications. In addition, the recent innovations leading to the introduction of better and more sensitive screening techniques (like ddPCR) have permitted the quantification and detection of low abundance targets in shorter times without requiring large numbers of replicates. This has established ddPCR as a tool of choice for liquid biopsies being utilized for breast cancer diagnosis. These developments are expected to fuel the market growth during the forecast period.
North America is Expected to Hold a Significant Share in the Market During the Forecast Period
The North American region is expected to hold a major share in the breast cancer liquid biopsy market. This is primarily due to the rising incidences of breast cancer and the growing demand for non-invasive treatment in this region.
According to the National Breast Cancer Foundation of the United States, in 2019, 62% of breast cancer cases were diagnosed at a localized stage. Female breast cancer represented approximately 15.2% of all new cancer cases in the United States. In the United States, Biocept, a molecular oncology diagnostics company, offers advanced methods for detecting circulating cancer cells (CTCs) and oncogene mutation fragments (ctDNA) in the blood. This allows CLIA-certified and CAP-accredited laboratories to perform predictive biomarker testing and provide the most up-to-date biomarker status from a non-invasive patient blood sample in breast cancer diagnosis, opening up opportunities in breast cancer liquid biopsy.
In July 2020, a group led by Canada-based Canexia Health launched a USD 1.9 million liquid biopsy screening initiative that aimed to improve access to testing and treatment options for Canadian cancer patients during the coronavirus pandemic. Initiatives like these are expected to affect the market development in a positive manner.
Furthermore, the high adoption rates of advanced diagnostic technologies such as PCR and NGS among healthcare professionals and the presence of well-established healthcare infrastructure are fueling the growth of the overall regional market to a large extent.
